Biogen’s litifilimab (BIIB059) has received FDA Breakthrough Therapy Designation for cutaneous lupus erythematosus, supported by Phase 2 LILAC results as the ongoing AMETHYST Phase 3 trial advances toward a potential first targeted CLE treatment.
Written By: Pharmacally Medical News Desk
Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to litifilimab (BIIB059) for the treatment of cutaneous lupus erythematosus (CLE). The designation highlights the urgent need for new, targeted therapies in a chronic autoimmune skin disease where no approved targeted options currently exist.
Litifilimab is a first-in-class, humanized IgG1 monoclonal antibody designed to target blood dendritic cell antigen 2 (BDCA2). This receptor is mainly expressed on plasmacytoid dendritic cells, which are known to play a key role in driving inflammation in lupus through the production of type I interferons and other immune mediators.
Major Need in Cutaneous Lupus
CLE is a serious autoimmune skin condition that can cause painful rashes, itching, photosensitivity, and long-term skin damage. Many patients experience irreversible complications such as scarring, hair loss, and pigmentation changes, which can significantly affect quality of life. Despite the burden of disease, CLE has no therapies approved specifically to modify its progression.
Victoria Werth, MD, from the Perelman School of Medicine at the University of Pennsylvania, emphasized the importance of the FDA’s recognition of CLE as a serious condition requiring better treatment options. She noted that current management relies heavily on topical steroids and antimalarials, leaving patients with limited alternatives when symptoms persist.
Phase 2 LILAC Results
The Breakthrough Therapy Designation is based on the totality of clinical evidence, including Phase 2 data from the LILAC study (NCT02847598), which were previously published in The New England Journal of Medicine. The trial showed that litifilimab significantly reduced skin disease activity in patients with CLE compared to placebo.
While current standard treatments such as immunosuppressants may help in controlling symptoms, they do not directly target the underlying immune mechanisms driving lupus-related skin inflammation.
Biogen Advances Phase 3 AMETHYST Trial
Biogen is currently evaluating litifilimab in the ongoing AMETHYST Phase 3 clinical trial (NCT05531565). The company expects a data readout in 2027, with the goal of bringing forward what could become the first targeted therapy approved for cutaneous lupus erythematosus.
Priya Singhal, MD, Biogen’s Head of Development, called the designation an important milestone and reinforced the company’s belief that litifilimab has the potential to offer substantial improvement over available treatment approaches.
Support from the Lupus Research Alliance
The Lupus Research Alliance welcomed the FDA’s decision, calling it an encouraging step toward accelerating therapies that may alter the course of disease. The organization highlighted the importance of including patient voices in clinical research and confirmed its collaboration with Biogen through Lupus Therapeutics in advancing clinical trials for CLE.
How Litifilimab Works
Litifilimab targets BDCA2 on plasmacytoid dendritic cells, reducing the release of inflammatory cytokines, including type I interferons. These immune signals are believed to be central drivers of lupus pathogenesis in both systemic lupus erythematosus (SLE) and cutaneous lupus.
The therapy remains investigational, and its safety and effectiveness have not yet been established by regulatory authorities.
About Cutaneous Lupus Erythematosus
CLE can occur with or without systemic lupus involvement and often affects women disproportionately. Around 90% of lupus patients are women, with symptoms frequently appearing between ages 15 and 40. The disease also has a higher impact on diverse ethno-racial populations, including African American, Asian, Hispanic/Latino, and Indigenous communities.
References
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options, 28 June 2026, Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options | Biogen
Victoria P. Werth et al, Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus, N Engl J Med 2022;387:321-331 Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus | New England Journal of Medicine
Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) (LILAC), ClinicalTrials.gov ID NCT02847598, Study Details | NCT02847598 | Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) | ClinicalTrials.gov
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST), ClinicalTrials.gov ID NCT05531565, https://clinicaltrials.gov/study/NCT05531565